Agoracom Blog Home

Posts Tagged ‘MMJ’

Namaste $N.ca $NXTTF Announces Submission of its Application to List on the NASDAQ $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:38 AM on Monday, July 23rd, 2018

  • Company has submitted its application to list its common shares on the NASDAQ Capital Market
  • In advance of the listing on NASDAQ, Namaste will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission

VANCOUVER, July 23, 2018  – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCQB: NXTTF) is pleased to announce that the Company has submitted its application to list its common shares on the NASDAQ Capital Market (“NASDAQ”).

In advance of the listing on NASDAQ, Namaste will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company’s common shares on NASDAQ remains subject to the approval of NASDAQ and the satisfaction of all applicable listing and regulatory requirements, including the effectiveness of the Form 40-F Registration Statement. The Company may also seek shareholder approval for a share consolidation in order to meet the share-price requirements of NASDAQ.

Namaste’s common shares will continue to trade on the OTCQB under the ticker symbol NXTTF until NASDAQ approval and uplisting, at which time the Company’s ticker symbol will change to NAMD.  Namaste’s common shares will continue to trade on the TSX Venture Exchange (“TSXV”) under the ticker symbol “N” post-NASDAQ uplisting.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We’re very excited to become one of the first Canadian cannabis companies to pursue this prestigious listing. Listing Namaste shares on NASDAQ will support the Company’s anticipated growth as we’re actively expanding our global business and entering into new sales channels. Namaste has certainly come a long way from humble beginnings and we’re very proud of our team and their accomplishments and are very much looking forward to elevating the Company’s profile by listing on NASDAQ.”

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). These forward-looking statements are based on current expectations and should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Examples of such statements include statements with respect to the timing, receipt of regulatory approval for, and listing of the Company’s common shares on a U.S. stock exchange and the filing of a Form 40-F Registration Statement with the United States Securities and Exchange Commission. Actual results could differ materially from those currently anticipated due to a number of factors and risks including, without limitation, those listed in the “Risk Factors” section of the Company’s annual information form dated February 6, 2018 and filed with the Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. The TSXV has neither reviewed nor approved the contents of this press release.

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-submission-of-its-application-to-list-on-the-nasdaq-300684729.html

SOURCE Namaste Technologies Inc.

Namaste $N.ca $NXTTF Announces New AI-Driven #Cannabis Mobile Strain Recommendation App Uppy Cannabis Journal $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:35 AM on Thursday, July 19th, 2018

  • Announced that the company has submitted applications to the Apple and Google Play stores in order to launch its latest mobile application, Uppy Cannabis Journal
  • Uppy Cannabis Journal is the first artificial intelligence (“AI”) driven medical cannabis app, which is designed to collect direct feedback on cannabis strains and over time provide strain and cannabis hardware recommendations

VANCOUVER, July 19, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the company has submitted applications to the Apple and Google Play stores in order to launch its latest mobile application, Uppy Cannabis Journal. Uppy Cannabis Journal is the first artificial intelligence (“AI”) driven medical cannabis app, which is designed to collect direct feedback on cannabis strains and over time provide strain and cannabis hardware recommendations. Namaste has implemented its AI technology through the Company’s wholly owned subsidiary Findify AB (“Findify” or “Findify.io”) and has fed over 2 million pieces of unique data to the platform which forms the base on which the algorithm will evolve and adapt itself to better understand the effects of cannabis strains in relation to treatment of many symptoms.

Through Uppy Cannabis Journal, Namaste’s customers and medical cannabis patients will have the access to journal their experiences using various strains of cannabis to treat their symptoms. The data collected over time will allow the algorithm to characterize the way different strains of cannabis benefit different people suffering from different symptoms. The goal of the Uppy Cannabis Journal is to develop a shopping experience whereby patients are provided with the best possible strain recommendations personalized for their needs, based on factual data collected through Namaste’s network of e-commerce sites, combined with user-feedback and AI technology.

Namaste will leverage its database of over 1.5 million consumers on a global scale to collect as much patient and strain data as possible. The implementation of AI technology in strain recommendations opens the door to a deeper level of understanding in how cannabis and different strain profiles treat medical symptoms. Namaste is well-positioned with its expansive international database of cannabis consumers to develop the Uppy Cannabis Journal app to a platform that ultimately will serve to benefit cannabis patients on a global scale. Once the app is approved by Apple and Google, Namaste will begin a marketing program to drive traffic from its own sites to Uppy Cannabis Journal and to attract new users through various digital marketing strategies.

The Company remains focused on developing innovative technologies like Uppy Cannabis Journal and NamasteMD, that provide value to Namaste and its shareholders but also bring great value to the industry, the Company’s peers and patients across the globe. Namaste is keen to differentiate itself in an industry focused on cultivation, as a leader in cannabis technology. Uppy Cannabis Journal provides Namaste with a tool to leverage its e-commerce platform to collect valuable data. Furthermore, the integration of Findify’s AI technology with Uppy Cannabis Journal is a ground-breaking event that will fuel a deeper level of understanding for cannabis patients.

Real-world applications of AI are best suited for implementation in e-commerce, healthcare and logistics environments. With Namaste’s large base of online traffic, the Company can collect substantial data in relation to cannabis patients and strains that will be leveraged using the most innovative AI technology in the market. Namaste will be the first company to dive deep into this exciting area of the industry and in enhancing the user experience for medical patients by providing more relevant recommendations based on the specific needs of individual patient’s. The Company will be able to immediately monetize the data collected by integrating Uppy Cannabis Journal with its e-commerce platform and its upcoming medical cannabis “sales-only” license through the Company’s wholly owned subsidiary and Access to Cannabis for Medical Purposes (“ACMPR”) applicant, Cannmart Inc.

Management Commentary

Chad Agate, CTO of Namaste comments; “The coming launch of Uppy Cannabis Journal represents the next phase of our integration of the Findify AI team into the Namaste platform core – applying machine learning models to help our users have the best cannabis experience in the world. I’m very proud of our world-class team of engineers and designers. We are spending time looking at how we are using technology today during interactions with our customers and focused on how the value of that moment could be increased. For the dedicated Namaste team, machine learning and AI is not about providing novel tools anymore, it is about creating a new type of organization. Our role model is Amazon, which has been able to apply its formula of automation, innovation and data-driven everything to solve seemingly unrelated business issues.”

Sean Dollinger, President and CEO of Namaste comments; “This is a very exciting moment for Namaste. Our acquisition of Findify will now show true value to the cannabis industry. Imagine having a platform which has been developed with millions of data points and that uses machine learning algorithms to gain a better understanding of the complex relationships between cannabis strain profiles and treating patient symptoms. We believe that that the Uppy platform will provide better strain recommendations for patients based on actual data that we can collect and analyze using some of the most advanced AI technology on the market today. Each cannabis strain has its own unique profile of cannabinoids and terpenes which define the characteristics of the particular strain and how it impacts patients on an individual basis.

Namaste is leading the industry in developing the most valuable technology platforms and in collecting data on a global scale that serves the Company, its consumers, patients and shareholders. I truly believe that this is something we should be proud of as a company and I feel confident Uppy will help better educate patients from across the globe by assisting them in making more informed decisions. We believe our users will find incredible value in this revolutionary educational tool which we will believe is essential in building patient trust and loyalty. Our ability to allow our patients real-time feedback is very exciting, as we once again lead the industry in new initiatives designed with a “patient first mentality” in mind. This was the last step needed in Namaste’s sales funnel and in creating a personalized consumer experience. I’d like to thank our Technology team at Namaste and our incredible CTO Chad Agate who continues to create and innovate incredible technology that will provide long term value to the Company.”

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press

SOURCE Namaste Technologies Inc.

INTERVIEW: Applied BioSciences $APPB.ca Discusses CBD and Pet health space $CGRW $APH.ca $GBLX $ACG

Posted by AGORACOM-JC at 11:51 AM on Wednesday, July 18th, 2018

Namaste $N.ca $NXTTF Signs E-Commerce and Technology Services Agreement with BlissCo Cannabis Corp $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:37 AM on Wednesday, July 18th, 2018

  • Company has signed an e-commerce and technology services agreement with BlissCo Cannabis Corp Inc.
  • Namaste will provide services including access to Namaste’s technology platforms, software integrations and e-commerce services including those powered by Namaste’s e-commerce artificial intelligence (AI) platform, Findify.io

VANCOUVER, July 18, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has signed an e-commerce and technology services agreement (the “Agreement”) with BlissCo Cannabis Corp Inc. (“BlissCo”) (CNSX: BLIS) (FRA: GQ4B:GR), whereby Namaste will provide services including access to Namaste’s technology platforms, software integrations and e-commerce services including those powered by Namaste’s e-commerce artificial intelligence (AI) platform, Findify.io.

Under the terms of this Agreement, Namaste will leverage its proprietary technology platforms to develop an innovative online marketplace in partnership with BlissCo to enhance BlissCo’s patient experience. BlissCo is a Canadian licensed producer and distributor of high-quality medical cannabis that operates an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) cultivation facility based in Langley, BC.

Namaste has developed industry-leading technology platforms which bring significant value to both the Company and the cannabis industry. This Agreement with BlissCo represents Namaste’s ability to enhance the consumer experience for its own customers and those of its industry peers.

Under the terms of the Agreement, Namaste will assist BlissCo in enhancing its online platform by utilizing Namaste’s suite of innovative technologies including;

  • Comprehensive audit of BlissCo’s e-commerce platform.
  • Enhancement recommendations to improve the user experience.
  • Software integrations including AI and machine learning through Findify.io.
  • Customization of Namaste’s telemedicine application, NamasteMD.
  • E-commerce development services including programming and IT.
  • Access to same-day delivery service through Pineapple Express Inc.

Blissco will compensate Namaste for services with 210,000 common stock options. Each option will have an exercise term of up to three (3) years.

Namaste is also pleased to announce that President and CEO, Sean Dollinger will join BlissCo’s board of directors. Namaste believes support from its management team will bring value to BlissCo’s board in areas of technology and e-commerce.

Namaste is focused on the development and acquisition of innovative technologies that will have a significant impact on the cannabis industry. As legalization of medical and recreational cannabis evolves globally and cannabis prices consolidate, Namaste will focus on technology and e-commerce innovations that can offer significant value to the Company and its industry peers. As many companies focus on cultivation, Namaste is establishing its position as a leader in e-commerce and technology in the cannabis industry.

Management Commentary

Damian Kettlewell, President and CEO of BlissCo comments; “By signing this partnership with Namaste, we are building yet another layer within the BlissCo Ecosystem that will enhance our connection with customers. This direct connection will provide a critical feedback loop to continuously improve our offerings, cultivate relationships and truly understand our customers. Providing a great experience is paramount for us and this technology gives us the tools we need to deliver that seamlessly.”

We’re also very pleased to have Namaste’s CEO Sean Dollinger join our board of directors and feel that Sean will bring great value and insight to our board and we look forward to expanding our relationship with Namaste in the future.

Sean Dollinger, President and CEO of Namaste comments; “We’re very proud to be partnering with Blissco and offering these services. We truly feel that the technology we’re developing will bring great value to others as well. We consider ourselves very fortunate to be breaking ground in exciting areas of technology including AI and machine learning within applications in the cannabis industry. Our technology platforms, like NamasteMD can also help all Canadians with more convenient access to medical cannabis from the comfort of their home.

We’re proud to be able to offer these platforms to partners and enhance their patient’s consultation and buying experience. We’re certainly looking forward to working with Blissco and their team who we believe are aligned with Namaste’s values and have great respect for their management team. Namaste will continue to create and acquire innovative technologies both domestically and abroad.

I’m honored to have the opportunity to join BlissCo’s board of directors and hope to provide significant value to their team in my role.”

About BlissCo Cannabis Corp.
BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) is an ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships.

BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets.

BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo’s future patients and customers.

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press

SOURCE Namaste Technologies Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2018/18/c1227.html

Namaste $N.ca $NXTTF receives approval of Normal Course Issuer Bid to repurchase and cancel up to 25,308,136 shares and announces attendance at #GritCAMP #cannabis & crypto conference July 25th-27th $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:49 AM on Monday, July 16th, 2018

  • Announced that the Company has received approval from the TSX Venture Exchange for a Normal Course Issuer Bid to repurchase for cancellation up to  25,308,136 common shares of its own capital through the facilities of the Exchange

VANCOUVER, July 16, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that the Company has received approval from the TSX Venture Exchange (the “Exchange”) for a Normal Course Issuer Bid (“NCIB”) to repurchase for cancellation up to  25,308,136 common shares of its own capital through the facilities of the Exchange. The NCIB will be in place for a 12-month duration, commencing on July 18th, 2018 and ending July 17th, 2019. Additionally, Namaste is also pleased to announce that the Company will attend and present at Grit Capital Advisory’s upcoming July 25-27th 2018 conference, GritCAMP.

Pursuant to the notice of intention filed with the Exchange, the Corporation intends to purchase for cancellation, through the facilities of the Exchange and at the market price of the Corporation’s common shares (“Common Shares”) at the time of purchase, up to 25,308,136 Common Shares, representing approximately 8.9% of the Company’s issued and outstanding common shares and 10% of the Company’s “public float” (as such term is defined in the TSX-V Corporation Finance Manual).

The NCIB will be conducted on behalf of the Company by Canaccord Genuity Inc. (“Cannacord”). The actual number of Common Shares that may be purchased and the timing of any such purchases will be determined by the Corporation and will be made in accordance with the requirements of the Exchange.

The Corporation will enter into a pre-defined plan with Cannacord to allow for the purchase of Common Shares by the Corporation at times when it ordinarily would not be active in the market due to internal trading blackout periods.

Namaste is pleased to announce that CEO Sean Dollinger will be presenting at GritCAMP’s upcoming cannabis and crypto conference on July 25th-27th, 2018. Grit Capital Advisory firm is well-known for its aggressive “out of the box” thinking. The conference will feature 20 of the most exciting crypto, cannabis, gaming & health-tech companies in North America and will feature +50 international wealth managers, 1×1 company circuit, immersive games and competitions, unique skill building in personal cyber-security, presenting with flair, tricks of the trade tax planning, live pyrotechnics entertainment and much more.

Genevieve Roch-Decter, CEO of Grit Capital comments: – “Cannabis and crypto are two of the most booming growth sectors in North America. Billions of dollars of capital are being invested into these industries with increasing institutional backing. Grit Capital prides itself on showcasing the right companies to the right people, in immersive settings where “fun” and “informative” intersect, driving strong investor engagement.”

To sign-up for GritCAMP, the crypto & cannabis markets and investments conference, visit www.gritcamp.ca

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: – “We believe that the present trading price of the Common Shares of the Namaste is at a significant discount to a what we believe is reflective of the Corporation’s value as a whole. Subsequently, management is of the view that it is in the best interests of all shareholders of the Corporation that, from time to time, Common Shares be acquired by the Corporation and returned to the treasury, thus increasing the Corporation’s value per Common Share for remaining shareholders.

We’re also very proud to have joined Grit Capital’s GritCAMP conference and I’m very much looking forward to presenting and participating in the event. Grit Captial’s management team have demonstrated themselves to be forward-thinking and innovative with respect to their platform and initiatives in the cannabis industry.”

About Grit Capital Inc.

Grit Capital is a capital markets advisory firm based in Toronto, Canada. In a nutshell: We “Tell the Right Story to the Right People” and “Incessantly Chase ROI”. We showcase our clients to investors through targeted 1×1 meetings, events, conferences, cross-north America roadshows and on social media. We pride ourselves on “out of the box” thinking to captivate mindshare. The intersection of “fun” and “informative” is where we and our clients thrive. We control our own messaging through our media platform, GritMedia, featuring a weekly newsletter that goes out to ~2k curated finance professionals. For further information about Grit Capital, please visit our corporate website at;

www.gritcapital.ca

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

 

On behalf of the Board of Directors

 

“Sean Dollinger”

 

Chief Executive Officer

 

Direct: +1 (786) 389 9771

 

Email: [email protected]

 

Further information on the Company and its products can be accessed through the links below:

 

NamasteTechnologies.com

 

NamasteMD.com

 

NamasteVapes.ca

 

Everyonedoesit.ca

 

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

Tetra Bio-Pharma $TBP.ca Targets Multi-Billion Dollar Fibromyalgia Market $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:44 AM on Monday, July 16th, 2018

Logo tetrabiopharma rgb web

  • Announced a co-development agreement with Storz & Bickel to use a specialized medical device known as the Mighty Medic,
    • Combination with its PPP001 prescription drug as well as with additional indications and a future proprietary cannabinoid formulation

Co-development deal announced with Germany’s Storz & Bickel aims to improve delivery of cannabinoid-based pain relief

ORLEANS, Ontario, July 16, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced a co-development agreement with Storz & Bickel to use a specialized medical device known as the Mighty Medic, in combination with its PPP001 prescription drug as well as with additional indications and a future proprietary cannabinoid formulation. The Mighty Medic is a portable herbal vaporizer for cannabis use approved by Health Canada as a Class 11 medical device and as such, is eligible for reimbursement. The agreement allows Tetra to effectively bring PPP001 to patients suffering from fibromyalgia and other chronic pain conditions, significantly expanding the market potential for PPP001.

Fibromyalgia affects about 4 million U.S. adults or about 2% of the adult population1. The cardinal symptom associated with the condition is pain that can be deep, sharp, dull, throbbing, or aching, affecting the muscles, tendons, and ligaments around the joints throughout the entire body. Treatments aimed at pain relief are the primary treatment intervention including an increasing use of opioids. Among the most commonly prescribed medications used to treat fibromyalgia are Lyrica, Cymbalta, Xyrem and Vimpat.

PPP001 is a cannabinoid-based product that is currently being studied in a Phase 3 Health-Canada approved clinical trial for advanced cancer pain. Tetra will use a bridging strategy to leverage the clinical data that has been generated with the smokable formulation of PPP001, to expedite the marketing requirements in these indications and reduce the time needed to bring these products to market. The combination product of PPP001 with the Mighty Medic would signify an important economic benefit for patients.

According to Dr. Gordon D. Ko, MD, FCFP(EM), FRCPC, PhD, “fibromyalgia is difficult to treat and there is no one “magic bullet”. As practitioners we have the daunting task of moving our patients from unrelenting neuropathic pain to improved function and a better quality of life,” said Dr. Ko. “The clinical use of medical cannabis in the management of fibromyalgia suggests these patients obtain significant relief. Moreover, the potential to reduce opioid use for these patients is a foremost consideration of using the Mighty Medic to deliver the cannabinoids and terpenes contained in PPP001 by inhalation.” Dr. Ko is Medical Director, Fibromyalgia clinics and Adjunct Lecturer at The Canadian Centre for Integrative Medicine, (Markham, Ontario) and Sunnybrook Health Sciences Centre, University of Toronto.

As a prescription drug, PPP001 will be eligible for insurance coverage. In Canada, only Class II, III and IV medical devices are eligible for reimbursement under provincial health care insurance programs.

Tetra and Storz & Bickel will also collaborate on the development of another inhalation cannabinoid-based prescription drug. The drug device combination product will target cancer patients and Tetra will use a similar bridging strategy to minimize marketing requirements and reduce time-to-market.

About Storz & Bickel
STORZ & BICKEL built the first factory in the world for the manufacture of medical herbal vaporizers in Tuttlingen, Germany, a town with almost 500 medical device manufacturers. Tuttlingen is reputed to be the center of medical technology, where the first factory to produce surgical instruments was established more than 150 years ago.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this or any other clinical trial, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation

 

Investor Relations Contact:
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
Tetra Bio-Pharma Inc.
514-817-2514
[email protected]

 

Media Contact:
energi PR
Carol Levine Lana Power
514-288-8500 ext. 226 416-425-9143 ext. 201

Namaste $N.ca $NXTTF announces domestic consulting agreement with Cannbit Ltd to expand Israeli operations and add new sales channels $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:18 PM on Thursday, July 5th, 2018

  • Signed a consulting agreement with Cannbit Ltd., whereby Cannbit will provide domestic consulting services to Namaste
  • Will streamline the Company’s Israeli operations, expand its platform and increase domestic revenues
  • Namaste has identified strong growth potential in its Israeli market and will focus on the expansion of its current platform as well as introducing new technology like its telemedicine application, NamasteMD and Findify’s AI technology in Israel

VANCOUVER, July 5, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce the Company has signed a consulting agreement (the “Agreement”) with Cannbit Ltd. (“Cannbit” or “Cannbitltd.com”), whereby Cannbit will provide domestic consulting services to Namaste that will streamline the Company’s Israeli operations, expand its platform and increase domestic revenues. Namaste’s recent announcement of its 10% investment in Cannbit, with Cannbit’s intention to publicly list on the Tel Aviv Stock Exchange (“TASE”), is further supported by this strategic partnership.

Namaste has identified strong growth potential in its Israeli market and will focus on the expansion of its current platform as well as introducing new technology like its telemedicine application, NamasteMD and Findify’s AI technology in Israel. Cannbit will provide Namaste with local resources to facilitate this growth. Cannbit will provide Namaste with domestic management and operations of the Company’s Israeli e-commerce platform, business development, website translations, domestic customer support services and wholesale sales. Cannbit’s team will work closely with Namaste’s marketing team to further develop its online platform and expand its B2B channels business in Israel.

Israel has quickly emerged as a global leader in cannabis research and development and Namaste is well positioned to leverage its technology and database of Israeli consumers to launch new initiatives in the Israeli market including the Company’s revolutionary telemedicine application and patient portal, NamasteMD. Through its investment with Cannbit, a medical cannabis supply agreement and now this strategic partnership, Namaste will benefit from expansion of its revenue streams, import of high-quality Israeli grown cannabis to the Canadian market (subject to approval by Israeli regulators and Health Canada), and also in leveraging its technology to provide simple and effective access to its online healthcare platform.

Management Commentary

Yaron Razon, co-founder and CEO of Cannbit comments: – “We are delighted to strengthen our strategic partnership with Namaste by adding yet another business cooperation them. Namaste is a global leader with a sensational management team. This Agreement, as well as our other partnerships with Namaste will benefit both companies as well as their respective shareholders. I’m also certain that both companies will find more ways to cooperate in the near future.”

Sean Dollinger, President and CEO of Namaste comments: – “We’re very proud of our various partnerships with Cannbit and love working with their team. This Agreement will bring great value to Namaste by leveraging Cannbit’s resources and expertise in the Israeli market. We see this is the beginning of a long-term relationship with our partner. We believe working with Cannbit under this Agreement is the best way for us to operate and grow in the Israeli market. As our database of Israeli customers grows every day, we look forward to launching new initiatives in Israel to capture more market share and in providing Israeli citizens with access to simple and convenient healthcare through NamasteMD. The idea for us is to keep building our database of customers, in order to overlap it with a domestic sales license and provide a fully-integrated platform for the sale of medical cannabis in the Israeli market. We’re looking forward to launching operations under the terms of this new agreement, exporting cannabis to the Canadian market when possible, and growing our Israeli division of the Company.”

About Cannbit Ltd.

Cannbit is focused on growing high-quality medical-grade cannabis with advanced technology and agriculture platform while utilizing the best human resources to produce the highest level of quality available that will effectively treat a wide range of illnesses. The Israeli government is expected to approve the export of medical cannabis and Cannbit intends to become Israel’s leading exporter for medical cannabis to legal jurisdictions around the globe. Cannbit’s facility is 10,000 square meters with an additional 13,000 square meters available for expansion and is located in Neot Hakikar, an area well known in the Israeli agricultural community with clear advantages in the cold seasons. Our cultivation is carried out in a sophisticated greenhouse that provides ideal conditions for a variety of cannabis strains. Cannbit’s management is comprised of a group of industry professionals in relevant disciplines.

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer pending receipt of a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

SOURCE Namaste Technologies Inc.

Namaste $N.ca $NXTTF Signs Services Agreement with Indigenous Canadian Medical Dispensaries (IcMD) to Provide Patient Consultations to Over 1.5 Million Indigenous Community Members Exclusively through NamasteMD $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:45 AM on Tuesday, July 3rd, 2018

  • Company has signed an exclusive Software Services Agreement (the “Agreement”) with Indigenous Canadian Medical Dispensaries Inc
  • Partnering with IcMD to provide all Indigenous communities across Canada (representing a population of over 1.5 million people) with free access to the Company’s revolutionary telemedicine application and online patient portal, NamasteMD

VANCOUVER, July 3, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce the Company has signed an exclusive Software Services Agreement (the “Agreement”) with Indigenous Canadian Medical Dispensaries Inc. (“IcMD” or “IcMD.ca”), whereby Namaste is partnering with IcMD to provide all Indigenous communities across Canada (representing a population of over 1.5 million people) with free access to the Company’s revolutionary telemedicine application and online patient portal, NamasteMD. The Company anticipates that this Agreement will drive further patient growth in Namaste achieving its target of acquiring over 50,000 medical cannabis patients by the end of 2018 and 200,000 by the end of 2019.

Under the terms of the Agreement, NamasteMD will provide IcMD with exclusive access to its online platform for Indigenous people across Canada, via both desktop and mobile phone platforms, on both Apple iOS and Android devices. In turn, IcMD has agreed to offer NamasteMD exclusivity for all its online patient consultations across Canada. As part of the Agreement, Namaste will use a unique code for IcMD to track patient acquisition from IcMD’s channels, and will offer medical cannabis, pharmaceutical products, as well as medical devices.

This Agreement represents a significant milestone, as Namaste and IcMD collaborate in providing Indigenous communities across Canada with the right to access medical cannabis. This will be accomplished by offering all community members with free consultations, whereby patients have instant access to doctors or nurse practitioners. Namaste and IcMD believe they can help bridge the gap for Indigenous communities across Canada who are suffering from an overwhelming lack of access to quality healthcare services. Through a platform powered by NamasteMD’s technology, IcMD plans to potentially provide healthcare access to over 1.5 million Indigenous peoples, many of whom currently reside in remote or rural areas, and have little to no access to comprehensive clinic services.

This Agreement embodies Namaste and IcMD’s belief that all Indigenous people across Canada, whether in urban environments or rural communities, should have proper access to healthcare practitioners and medical cannabis.  IcMD’s management team is committed to supporting Indigenous communities and believes NamasteMD will serve as a powerful tool to enhance the lives of many members. Both Namaste and IcMD view this partnership as an incredible opportunity to become leaders in the Indigenous medical cannabis and direct healthcare space by providing people with safe and reliable access to healthcare in their hands.

Namaste views this opportunity as potentially one of the most significant initiatives it has embarked on to date. Once deployed, Namaste believes its platform has the ability to have a significant social impact on Indigenous communities across Canada. Namaste and IcMD are also confident this technology has the ability to catch the attention of Indigenous leaders on a global scale once its effects are observed within the Canadian market. This represents a unique opportunity for both parties to come together and work with Indigenous leaders across the country in helping drive social reform.

At a time when political leaders at all levels of government have acknowledged an impending opioid epidemic, it would appear that there is no better time to implement better access to healthcare. By making it easier and more affordable to access doctors and nurse practitioners, it is believed that this will allow Indigenous members, whose communities have been some of the hardest hit, the ability to make more informed choices under the guidance of a trained professional.

The fact that the Indigenous market and its people have consistently been left out of equal access to healthcare is something Namaste and IcMD are extremely excited to change. Starting with nationwide access to medical cannabis and moving forward to health consultations and treatment plans Namaste & IcMD will truly be putting healthcare in the hands of the people.

Namaste’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) is a late-stage applicant for a medical cannabis “sales-only” license that will serve to provide a diverse selection of cannabis from preferred cultivation partners and will be integrated with IcMD’s platform through NamasteMD upon receipt of its sales license.

IcMD and Namaste are excited to attend and launch IcMD at the Assembly of First Nation’s 39th General Assembly in Vancouver, BC July 23 to 26, 2018. Namaste and IcMD will be highlighted in a booth at the AFN Circle of Trade. The AFN Circle of Trade provides the opportunity to meet, network and showcase products to over 4,500 key decision makers and influencers from a growing market within the First Nations communities across Canada.

The Assembly of First Nations (AFN) is a national advocacy organization representing First Nation citizens in Canada, which includes more than 900,000 people living in 634 First Nation communities and in cities and towns across the country. http://www.afn.ca/about-afn/

Namaste is pleased to be hosting a special edition Namaste420 Youtube live-stream at 9:00 AM EST on July 3rd, 2018 to discuss the Agreement with IcMD and answer questions. To join the stream please visit the link below;

https://www.youtube.com/watch?v=SOJb-uO-OXg

Management Commentary

Christopher Henry, CEO of IcMD comments: “As a proud member of the MMF I have been consistently involved in Indigenous employment and advancement to towards complete self-sufficiency. For the past 25 years, I have worked closely with and in Indigenous communities across Canada. During that time, I have personally seen the lack of access to almost every service most Canadians take for granted every day. By partnering with Namaste Technologies and NamasteMD we are able to gain access to technology that would allow us to realize our dream of putting healthcare in the hands of the people. This has the potential to change how we provide healthcare to Indigenous communities across Canada and bring them one more step to equality with all Canadians.”

Christopher Henry is a member of the Manitoba Metis Federation and co-owner of WorkingWarriors.ca a national Indigenous Engagement and Employment Company.

Michael Birch, President, and COO of IcMD comments: “I grew up in Garden Hill First Nation. A fly in remote community in Northern Manitoba with over 3000 residents. We didn’t have access to a doctor or nurse or even a healthcare facility at times. To be able to put access to reliable secure healthcare in the hands of our people is a dream I didn’t think would ever happen in my lifetime. By partnering with Namaste and NamasteMD we will finally be able to give all Indigenous people, regardless of location, access to a more equal standard of care.”

Michael Birch is an entrepreneur originally from Garden Hill First Nation. He is owner & President of MBE a Facility Management and Logistics Company for Indigenous communities.

Sean Dollinger, President and CEO of Namaste comments: “We are beyond honored to have partnered with IcMD and their management team who exemplify the nature of Namaste and our core values. We truly believe that our technology will improve the health and well-being of hundreds of thousands of people in Indigenous communities across Canada. The level of accessibility to high-quality healthcare that we will be able to offer has the ability to create a significant social impact to all Indigenous communities. We are proud to be partnered with IcMD’s management team who are deeply committed to this cause.

This Agreement is just the start of what we feel will evolve into a long-term relationship and success in bringing value to the lives of many Indigenous people. While the legalization of recreational cannabis may not be accessible to community members across Canada, Namaste will serve to provide convenient access to medical cannabis in remote areas not yet served by the recreational market.

For IcMD to select Namaste among hundreds of ACMPR Licensed Producers in Canada, speaks volumes as to the value in our technology and we feel privileged to embark on this new and exciting initiative for the betterment of all Indigenous communities and its members. We’d like to thank IcMD’s team, Christopher Henry and Michael Birch for their support and hard work in putting together this exciting partnership.

We’re also pleased to announce the submission of the TSX Venture Form 5G at the close of the market on Friday, June 29th, 2018, and we anticipate commencing our Normal Course Issuer Bid (“NCIB”), whereby the Company will purchase up to 25,308,136 of its common shares, or 8.9% of the “Public Float” (as such term is defined in the TSX-V Corporation Finance Manual).”

About Indigenous Cannabis Medical Dispensaries Inc.

IcMD’s goal is to put reliable and accessible healthcare in the hands of Indigenous people. By working with our relationships created over a lifetime of work in the Indigenous community IcMD will bring medical cannabis to every region of Canada. We believe that the over prescription of pharmaceuticals to our people has had a negative effect on our communities. By offering a natural solution to many common conditions we believe will we be more able to return to our traditional roots. Moving towards health consultations and treatment plans will eventually see IcMD as the nationwide leader in direct Indigenous healthcare equality.

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer pending receipt of   a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

SOURCE Namaste Technologies Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2018/03/c4242.html

Tetra Bio-Pharma’s $TBP.ca Evidence-Based Business Model Confirmed $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:13 AM on Friday, June 29th, 2018

Logo tetrabiopharma rgb web

  • Announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model.
  • Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence

Tetra Bio-Pharma provides extension to North Bud Farms

ORLEANS, Ontario, June 29, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model.  Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence. As a biopharmaceutical company, Tetra’s orientation is to bring cannabis and cannabinoid-based products to market that meet the regulatory quality, safety and efficacy requirements for prescription medications.

Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids. In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra to collect significant data to support its marketing applications. A similar clinical development program was launched with cannabis oils in preparation for the upcoming post-legalization market.  The combination of safety, pharmacokinetic and efficacy data allows Tetra to bring products to market under the proposed new regulatory framework.  Tetra Bio-Pharma is one of a few cannabinoid based companies that is committed to providing much needed clinical data for both its pharmaceutical and natural health products.

Over the coming months Tetra Bio-Pharma will deliver its findings in a series of presentations and scientific articles that will be published in 2018 to share the clinical data of both the inhalation and oral clinical development programs with the medical community,  beginning with the July 4, 2018 International Cannabinoid Research Society Meeting in the Netherlands where Dr. Maria-Fernanda Arboleda, MD, will present the results of the above clinical trial. http://www.icrs.co/SYMPOSIUM.2018/ICRS2018.PRELIMINARY.PROGRAMME.pdf ).  Tetra is a Gold Sponsor of this prestigious congress.

Update on North Bud Farms Inc.

Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the receipt of North Bud’s preliminary and final prospectus.  As one of the closing conditions to the sale these documents must now be submitted by July 31, 2018.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514

Media Contact:
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209

Namaste $N.ca $NXTTF Announces Intention to Commence a Normal Course Issuer Bid to Repurchase Up to 10% of its Public Float and Provides a Corporate Update Including Incoming CFO, New Board Director and Consultants $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:48 AM on Thursday, June 28th, 2018

  • Subject to regulatory approval, it intends to commence a normal course issuer bid 
  • The Company intends to purchase up to 25,308,136 common shares, representing approximately 8.9% of the Company’s issued and outstanding common shares and 10% of the Company’s “public float”

VANCOUVER, June 28, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that, subject to regulatory approval, it intends to commence a normal course issuer bid (“NCIB”). The Company intends to purchase up to 25,308,136 common shares, representing approximately 8.9% of the Company’s issued and outstanding common shares and 10% of the Company’s “public float” (as such term is defined in the TSX-V Corporation Finance Manual).

The Company is in the process of appointing Canaccord Genuity Inc. as its broker to conduct the NCIB on its behalf. The NCIB will commence three business days following the TSX-V’s acceptance of the Company’s Notice of Intention to commence the NCIB.

All purchases will be made through the facilities of the TSX-V at market prices and otherwise in accordance with the rules and policies of the TSX-V. All common shares acquired by the Company under the NCIB are being purchased for cancellation.

Namaste’s board of directors believes that, from time to time, the market price of the common shares does not adequately reflect the Company’s underlying value and future prospects and that, at such times, the purchase of the common shares represents an appropriate use of the Company’s financial resources and will enhance shareholder value.

In addition to the NCIB, the Company is pleased to announce the appointment of Kenneth Ngo as the Company’s CFO and the appointment of Fern Glowinsky, president of Merrco Payments Inc. (“Merrco”) to the Company’s board of directors. Namaste has also engaged advisory consultants including Tim Henley and Dr. Paul Neider (DVM) who are focused on launching CBD production for both human and pet consumption in Namaste’s international markets. Additionally, the Company’s board of directors has approved new stock options grants in accordance with the Company’s stock option plan.

CFO Appointment

The Company is also pleased to announce the appointment of Kenneth Ngo as Namaste’s CFO. Kenneth Ngo joined Namaste Technologies Inc. as a corporate controller in April 2018.  He has more than 20 years of experience in finance and has held positions of increasing responsibility in a number of US and Canadian publicly traded companies.  He received his Chartered Accountant designation while working for Deloitte LLP.  Mr. Ngo is a graduate of Simon Fraser University in British Columbia, with a Bachelor of Business Administration degree. He is a member of the Chartered Professional Accountants of Ontario and a U.S. Certified Public Accountant in the state of Colorado.

Mr. Ngo, Namaste CFO comments: “I’m thrilled to being part of an exciting journey. Namaste is a true visionary of technology platforms that is well positioned for significant growth.”

Subsequently, Mr. Philip Van der Berg has submitted his resignation as Namaste CFO and the Company would like to take the opportunity to thank him for his service and wish him best of luck on his future endeavors.

Board Appointment

The Company is pleased to announce the appointment of Fern Glowinsky, CEO of Merrco to its board of directors. Namaste has been a client of Merrco for several years and is proud to have their CEO join the board. Fern Glowinsky joined Merrco in March 2018 following its acquisition of Payfirma Corporation. Merrco and Payfirma are committed to helping established and emerging businesses thrive through access to payments technology. Ms. Glowinsky has extensive payments sector experience, spending 15 years as a senior executive at Moneris, most recently as COO with accountability for enterprise operations, passionately focused on transforming customer experience. In 2016 Ms. Glowinsky joined Cliffside Capital as CEO and Director, managing its investments in the alternative lending sector. Ms. Glowinsky is a graduate of the joint MBA/JD program at Schulich School of Business and Osgoode Hall Law School and holds the ICD.D designation.

Fern Glowinsky, comments: “With Merrco’s dedication to enabling payments in the cannabis sector, I’m extremely excited to be joining Namaste’s board and partnering with Sean, his team and the rest of the board as Namaste continues its mission of innovating cannabis technology solutions globally, while delivering a better user experience.”

Advisory Consultants

Subject to TSX-V approval, Namaste is planning on launching the sale of CBD products in international markets, particularly in the under-serviced markets in the UK and EU and has been working hard to develop new sales channels. As such, Namaste has engaged two consultants, Tim Henley and Dr. Paul Neider who provide valuable resources that will have a direct impact on the success of such endeavors. These two appointments will help Namaste in launching CBD products for both human consumption and for animal applications, as Dr. Neider is a doctor of veterinary medicine and supporter of CBD use to support the well-being of pets and animals.

Tim Henley has spent the last 3 years researching and studying the Cannabinoid space and trends. His research in CBD (Cannabidiol) lead him to become a Director of the UK’s Cannabis Trades Association.  Tim was instrumental in helping organize the early days of the association and its membership. He subsequently stood down to pursue a more radical approach to economic development and cannabis reform. Tim has been actively engaged in working with Namaste to assess the regulatory requirements for the sale of CBD products in the UK and has provided advisory services to both Namaste and its partners in the context of packaging and marketing of CBD products. Tim’s role with Namaste outside of his consultancy will be procuring the highest quality CBD products for the Company’s e-commerce marketplace.

Tim Henley, Namaste’s New Products Manager comments: “I came across Namaste when developing my business. I wanted to sell vaporizers and found Namaste to be a really easy modern company to deal with and set up my own company, Cannablyss Ltd.  I would often talk to Kory Zelickson, co-founder, as I placed my wholesale orders. I am an evangelist for 21st Century Cannabis and its potential to help humanity fix so many of the ills of modern society. Be it the revolution in our understanding of the Endocannabinoid system and how this affects our bodies in so many ways. We need to nourish our minds and bodies with Phyto cannabinoids not pharmaceuticals. The changes I have seen in the industry are nothing compared to what is coming. Namaste is helping to create the future and it’s the most exciting and dynamic company I have ever worked for. Namaste is going to change the world building a sustainable future!!”

Paul Neider is an accomplished veterinarian and serial entrepreneur.  Being the founder of three veterinary hospitals, three other companies, shows Paul’s creativity and ability to diversify into various fields. He is passionate about helping animals (humans too) which carries through to his activities with Namaste.  He will work at a task until perfection and never stops learning. Dedicated, enthusiastic and fun to be around, living with four dogs reminds him to just chase a ball once in a while!

Paul Neider, DVM comments: “The team at Namaste is one of the most innovative and passionate group of entrepreneurs I’ve met in a long time. By joining them I will help expand the company into the very large veterinary/pets market.”

Stock Option Grant

Subject to the terms of the Company’s Stock Option Plan, Namaste’s board of directors has approved the issuance of 2,515,000 options to a number of employees and consultants of the Company. All options are exercisable at a price of $1.32 per common shares for a period of five years. The options will vest in quarterly instalments over a two-year period.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to announce strengthen Namaste’s corporate governance team by announcing the appointment of Kenneth Ngo as our new CFO and Fern Glowinsky to our board of directors. Both Kenneth and Fern will provide great value to the company in their respective roles. We believe that Namaste is remains in the infancy stage of our development as a technological leader in the global cannabis industry and as such are pleased to announce our intentions to commence a NCIB to buy back and cancel up 10% of the Company’s “public float”. Furthermore, we’re very pleased to bring on Tim Henley and Paul Neider to lead the launch of high-quality CBD products in our platform for both human and animal use. CBD products have been proven effective in treating many conditions and in improving overall health and well-being.

We’d like to take the opportunity to thank everyone for their support and to welcome new members to the team. We are very excited about the future of the Company and look forward to many milestones to come. Namaste is constantly evolving and adapting to the changing landscape of this exciting industry that we are very proud to be a part of.”

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer pending receipt of   a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

SOURCE Namaste Technologies Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2018/28/c3500.html

 

Sean Dollinger, Chief Executive Officer, Direct: +1 (786) 389 9771, Email: [email protected] CNW Group 2018